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The aim of cancer screening programmes is to reduce mortality.
Randomized controlled trials have shown that mammographic
screening can reduce breast cancer mortality by 20–30% (Tabar et
al, 1985), the benefit deriving from the reduction in tumour size,
extent of axillary node involvement and possibly malignancy
grade associated with earlier diagnosis (Chen et al, 1997; Tabar
et al, 1999). Thus the effectiveness of screening is already estab-
lished. The question of interest now, however, is the extent to
which the benefit can be achieved in the population setting by a
given screening programme. Specifically how does the perform-
ance of the East Anglian regional programme compare with the
results obtained in the trials? 
Introduced in 1989, the NHS breast screening programme
(NHSBSP) aims to reduce breast cancer mortality in the invited
population by at least 25% by the end of the year 2000 (Secretary
of State for Health, 1992). However, assessing the impact that
screening has on the target population is difficult. Simply mon-
itoring breast cancer mortality before and after the introduction of
screening is unsatisfactory because factors other than screening
also influence mortality. Improvements in treatment (Beral et al,
1995; Peto et al, 2000), earlier diagnosis resulting from increased
breast awareness (Stockton et al, 1997), and changes in the under-
lying disease due to variation in exposure to breast cancer risk
factors (e.g. oral contraceptives, number of children, age at first
birth etc.) (Henderson et al, 1996) influence incidence and there-
fore mortality. Furthermore, even given a suitable unscreened
comparison group, assessing screening programme impact by
monitoring deaths is unsatisfactorily slow because breast cancer
survival is relatively high (Coleman et al, 1999). Mortality
amongst invited women in the Swedish two-county study was not
significantly lower for 6 or 7 years (Tabar et al, 1987); similar
information for the UK programme will be delayed further owing
to the staggered introduction of screening (McCann et al, 1998). 
When evaluating screening programmes, we must therefore
address two issues: 1) how to measure only changes in mortality
specifically attributable to screening and, 2) how to avoid the
delay and uncertainty associated with measuring deaths. 
Addressing the first issue, we require two groups of women
with similar exposure to breast cancer risk factors (age, social
class, number of children, etc.) but different exposure to screening
invitation (i.e. one invited group, one uninvited). Treatment will be
similar between groups if cancers are diagnosed within the same
time period, thus any difference in outcome should be attributable
to screening programme activity. Such groups were available in
East Anglia when the programme started due to its staggered intro-
duction across the region, since each district within the region set
up its own screening centre individually. The first centre to start
screening in the region did so early in 1989, completing the first
round in 1993, and the second round in 1996. The last centre
commenced two years later, in 1991, finishing the first round in
1995, and the second in 1998. It thus took 6 years to complete an
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entire first round in the region. Furthermore, women were invited
by year of birth, in 5-year age bands, over a 3-year cycle starting
with the oldest (McCann et al, 1998). Thus, although between
1989 and 1996 all but one screening unit had completed two
rounds of screening, a substantial number of cancers were dia-
gnosed in women awaiting their first invitation. In this period, one
birth cohort of women eligible for at least two screening rounds
therefore provided us with two comparable groups of cancers: one
diagnosed in women already invited for screening and the other
diagnosed in those awaiting invitation. 
Addressing the second issue – one alternative to direct observa-
tion of mortality is to compare the prognosis of cancers between
invited and uninvited groups. Together with survival information,
the difference in prognosis may be used to estimate a difference in
mortality. Results from randomized screening trials have shown
that the prognostic factors tumour size, node status and malig-
nancy grade can be used accurately to predict subsequent mortality
(Tabar et al, 1995). 
Using data from the East Anglian programme, we have
compared the distribution of prognostic factors in two groups of
cancers; one diagnosed before, and one after, first invitation for
screening. We have then determined the reduction in mortality
predicted by the observed difference in prognosis between these
two groups. Here, we describe the shift in prognosis that has been
brought about by screening and report the associated mortality
reduction expected to result from the second round of breast
screening in East Anglia. 
METHODS 
We studied cancers in both invited and uninvited study groups,
diagnosed over the period 1.1.89–31.12.96, in women born
1925–43 and eligible for invitation to the first and second rounds
of the East Anglian breast screening programme. Our aim was to
compare two groups of newly incident cancers. In the uninvited
group cancers which arise are, by definition, newly incident since
there is no screening. In the invited group we can construct a set of
newly incident cancers by excluding the prevalent cases diagnosed
at the initial screen, and including those diagnosed during one
screening cycle i.e. from the time immediately after the first
scheduled screening appointment to the time immediately
following the second. This yields a set of incident tumours from a
complete incidence cycle of a screening programme (interval
cancers plus cancers in non-attenders plus cancers detected at the
second screening): the so-called ‘unbiased set’ (Tabar et al, 1992).
These cancers were identified as described previously (McCann
et al, 1998). In this manner we have excluded cancers detected at
the initial screen, which include a disproportionate number of slow
growing cancers of good prognosis (so called ‘length bias’
(Morrison, 1992)). 
Eligible women were identified on the breast screening
computer system. Of those invited to first screen, around 27%
exceeded the upper age limit for invitation (65 years) at the time a
second screen would have been due. These were excluded from
the analysis, as were women who failed to respond to the initial
invitation but who attended for the first time upon reinvitation, 3
years later since, for the latter group, the scheduled 3-year repeat
screen would, in fact, be an initial (prevalence) screen. 
Since the introduction of screening was staggered by district
and by year of birth, as described earlier, there was a substantial
number of women in the region in the age group targeted for
screening who were not actually invited for mammography until
some years after the beginning of 1989. Cancers diagnosed in
such women before their first invitation to screening formed the
uninvited group. 
Information on the prognostic characteristics size (maximum
diameter of invasive component), grade (classified according to
ICD-0 (World Health Organisation, 1990)) and node status were
obtained from the Cancer Registry, breast screening units and
medical records. 
Predicting mortality based on prognosis requires knowledge of
the baseline (underlying) survival and on the age-adjusted effects
of tumour size, grade and node status on this baseline survival. We
obtained this information using Cox’s proportional hazards
survival analysis (Cox, 1972) of a reference cancer population: the
entire East Anglian study set of 1401 invasive cancers. We also
repeated the analysis using a separate reference population (1528
invasive cancers diagnosed in the period 1977–88 from both
arms of the Swedish Two-County trial in women aged 50–69
at randomization, of which 768 were screen-detected and 760
symptomatic). 
For the reference population, we estimated a baseline survival at
88 months. A ‘prognostic score’ was then estimated for different
combinations of categories of tumour size, grade and node status
(including ‘missing’) using this baseline and the relevant hazard
ratios (Tabar et al, 1995). This prognostic score indicated the
overall probability of death for a cancer case at 88 months based
on its size, grade and node status. Total deaths expected in the
invited and uninvited groups were calculated by combining the
number of cancer cases in each category with the prognostic score
estimated for that category. Adding deaths over all categories
within each group gave the total predicted deaths (Tabar et al,
1995). Relative mortality was obtained by dividing the predicted
death rate (= deaths 4 cancers) in the invited group by that
predicted in the uninvited group. Confidence intervals were esti-
mated assuming a multinomial distribution for the 112 possible
prognostic classes (7 size ´ 4 node status ´ 4 grade) (Day and
Duffy 1996). 
Predition of mortality from the tumour size, grade and node
status has been repeatedly validated and has been shown to be
accurate in terms of both absolute numbers of deaths and of the
relative risk of death for an invited group compared with a group
not invited for screening (Organising committee and collaborators,
1996). 
For screen-detected cancers, survival times are artificially
increased by ‘lead time’ (Morrison, 1992), since their diagnosis
has been advanced by screening. If earlier treatment conferred no
additional benefit whatsoever over later treatment, women with
screen detected cancers would die at exactly the same point in time
as they would have, had they not been screened. They would still,
however, show longer survival from diagnosis, the increase in
survival time representing the amount of time by which screening
advanced the time of diagnosis. The length of this lead time in the
East Anglian programme is unknown but, in the Swedish two-
county study, is estimated to be around 3 years in these age groups
(Tabar et al, 1995). Given the relative detection rates in the
Swedish two-county study and the East Anglian programme (Day
et al, 1995) it is unlikely that the average lead time in the East
Anglian programme falls outside the 24–36 months range. To
adjust for it when calculating relative mortalities, baseline survival
for screen detected cancers was estimated, not at 88 months, but at
124 months, corresponding to adjustment for 36 months of leadtime. Adjustment for an intermediate lead time (24 months) was
also made. 
RESULTS 
Of 203 194 women born between 1925–43 and invited to the first
screening round, 140 387 were reinvited to second screen. A total
of 451 invasive cancers occurred after 1 January 1989 and before
receipt of first invitation to screening. These formed the uninvited
group. 571 invasive cancers were detected at first screen and were
excluded from the analysis. During the study period, in the invited
group, there were 382 interval cancers presenting after first screen,
156 cancers in non-attenders at first screen, and 412 cancers
detected at second screen: a total of 950 invasive breast cancers.
The total study set (invited plus uninvited) therefore comprised
1401 cancers. The numbers of women invited and screened at the
second screen are given by age at first invitation in Table 1, which
also shows numbers of cancers diagnosed in each study group, by
age at diagnosis. The mean age (standard error) at diagnosis for
women in the uninvited group was 55.3 (0.16; range 50.0–63.9)
and in the invited group was 58.5 (0.12, range 50.2–65.1). 
The distributions of tumour size, grade and node status in each
study group are shown in Table 2 and Figure 1. Tumour grade, size
and node status were all more favourable in the invited group. The
relative risks of death by size, grade and node status, for the East
Anglian reference group, are given in Table 3: these increased with
increasing tumour size, grade and node involvement. Numbers of
deaths predicted in each study group, and estimated relative
mortalities, are given in Table 4. After adjusting for 36 months’
lead time amongst screen-detected cancers, estimated relative
mortality in invited women aged 50–64 at diagnosis, compared
with uninvited women, was 0.85 (95% CI 0.78, 0.93), see Table 4.
For women aged 50–54, the corresponding relative mortality was
0.93 (0.80, 1.08); and for those aged 55–64, it was 0.81 (0.72,
0.91). Very similar reductions were predicted by using prognostic
hazards from the Swedish reference population (data not shown).
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Table 1 Women invited and screened in the second screening round, by age at first invitation, and cancers arising in invited and uninvited study groups, by
age at diagnosis 
Invited group Whole study group 
Cancers in  Cancers in invited group 
uninvited group
Age at first Women invited to  Women screened at  Age at  Intervals Non-attenders Second screen  Invited
invitation second screen second screen diagnosis detected group total
<50 3085 2331 <50 0 0 0 0 0 
50–54 55 444 41 685 50–54 225 114 38 54 206 
55–59 56 439 41 002 55–59 184 150 64 164 378 
60–64 25 419 16 003 60–64 42 116 54 94 364 
65–69 0 0 65–69 0 2a 00 2  
<50–64 140 387 101 021 50–64 451 382 156 412 950 
aThese cancers occurred in women aged 62.1–62.3 at first screening. 
Table 2 Numbers of cancers and percent of cases with known information in invited and uninvited study groups according to tumour size, grade and node
status 
Study groups 
Invited Uninvited 
Prognostic  Category <55 55+ all ages <55 55+ all ages 
characteristic
n % n % n % n % n %  n % 
Size (mm) 1–9 25 13 110 16 135 15 8 4 8 4 16 4 
10–14 32 17 146 21 178 20 24 13 24 13 48 13 
15–19 37 20 163 23 200 23 41 22 32 17 73 19 
20–29 51 27 154 22 205 23 66 35 69 36 135 36 
30–49 28 15 93 13 121 14 34 18 38 20 72 19 
50+ 16 8 28 4 44 5 17 9 19 10 36 9 
Missing 17 – 50 – 67 – 35 – 36 – 71 – 
Total 206 744 950 225 226 451 
Node status Negative 100 60 326 59 426 60 70 51 58 48 128 50 
Positive 60 36 197 36 257 36 60 44 57 48 117 46 
Metastases 6 4 25 5 31 4 7 5 5 4 12 5 
Missing 40 – 196 – 236 – 88 – 106 – 194 – 
Total 206 744 950 225 226 451 
Grade 1 29 19 157 28 186 26 20 20 10 10 30 15 
2 78 50 272 49 350 49 49 49 51 50 100 50 
3 49 31 125 23 174 25 31 31 40 40 71 35 
Missing 50 – 190 – 240 – 125 – 125 – 250 – 
Total 206 744 950 225 226 451 Greater mortality reductions were predicted if adjustment for a
shorter lead time was made (adjustment for 24 months’ lead time
gave a relative mortality (95% CI) of 0.81 (0.74, 0.89) for women
aged 50–64; 0.91 (0.78, 1.06) for those aged <55, and 0.76 (0.68,
0.84) for those aged 55–64). 
DISCUSSION 
As a consequence of the more favourable tumour size, grade and
node status of cancers in the invited study group, we predict that
mortality amongst breast cancers diagnosed in women aged 50–64
following invitation for screening will be at least 15% (95% CI 7,
22%) lower than for cancers diagnosed in the same population
before invitation to screening. 
For women aged 55 or older at diagnosis, the predicted reduc-
tion is greater (19%), whereas for women aged under 55, it is small
(7%) and not significant, as noted previously in other screened
populations and attributed to the reduced sensitivity of screening
and faster rate of tumour progression in these younger women
(Tabar et al, 1995; Duffy et al, 1996). These predictions may
underestimate the true impact of screening, since the 3 years’ lead
time allowed to adjust for the earlier diagnosis of screen detected
cancers in the invited group may be an overestimate. Allowing just
2 years’ lead time for the screen detected cases would predict a
19% mortality reduction in the entire age group, and a 24% reduc-
tion in women aged over 55 at diagnosis. 
A recent paper (Blanks et al, 2000) has estimated using
observed mortality rates that in 1998, in women aged 55–69, the
reduction in breast cancer mortality due to screening was 6.4%.
This reduction derives from screening at the initial round. Our
results refer to screening after the initial round and predict the
reduction in breast cancer mortality in the future. They suggest an
improvement in the performance of the screening programme after
the initial round, already noted nationally in increased cancer
detection rates (Young et al, 1997). 
Women in the invited group were, on average, 3 years older at
diagnosis than those in the uninvited group. This difference arose
because older women were invited for screening first, giving less
time in which cancers could present before invitation. This
difference in age should not affect results, however, because we
adjusted for age group at diagnosis when estimating hazards asso-
ciated with prognostic characteristics, and have also presented
age-stratified results. The age-adjusted relative mortality is iden-
tical with the unadjusted (i.e. 0.85) with a slightly wider 95%
confidence interval (0.77, 0.94). 
Our results indicate that the second round of the East Anglian
breast screening programme is likely to deliver a 15% reduction in
breast cancer mortality, falling short of the 25% reduction
expected from the randomized trials. In the age group 55–64,
however, a reduction more in line with the trial results is predicted.
It should be understood, however, that these results pertain to the
first few years of the programme. It may be that changes in
practice at screening (e.g. higher film density) and at assess-
ment (e.g. greater experience of percutaneous biopsy) may have
improved the sensitivity of screening, thus more recent results
might demonstrate a greater benefit. The results here, however, are
the most reliable available for the East Anglian programme and
they suggest room for improvement, notably in women aged under
55. Table 2 suggests that sensitivity to small tumours needs to be
improved in these younger women. Some improvements have
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Table 3Estimates of relative hazards (with 95% confidence intervals)
based on proportional hazards regression, with each factor adjusted for the
others and for age group, for all invasive cancers in the East Anglian
reference group 
Prognostic characteristic Adjusted relative hazard (95% CI) 
Size (mm) 
1–9 0.37 
(0.17, 0.80) 
10–14 0.52 
(0.32, 0.85) 
15–19 0.87 
(0.61, 1.25) 
20–29 1.00a
30–49 1.34 
(1.97, 1.85) 
50+ 2.28 
(1.56, 3.33) 
missing 1.27 
(0.88, 1.83) 
Node status 
negative 1.00a
positive 3.88 
(2.90, 5.38) 
metastases 11.60 
(7.30, 18.45) 
missing 2.04 
(1.44, 2.89) 
Grade 
1 0.29 
(0.15, 0.58) 
2 1.00a
3 1.50 
(1.09, 2.06) 
missing 1.22 
(0.27, 1.63) 
aReference category. The baseline survival predicted by the regression for
the reference group was 0.88 at 88 months (no adjustment for lead time) and
0.83 at 124 months (adjusting for 36 months lead time), for Grade 2, node
negative, size 20–29 mm tumours. 
Table 4Total deaths predicted after 88 months based on tumour size, histologic grade and lymph node status, using relative hazards from Table 3, with
adjustment for 3 years of lead time 
Age Study group Breast cancer cases Total deaths predicted Predicted deaths per 100 cases Relative mortality (95% CI) 
<55 Uninvited 225 65.87 29.3 0.93 
Invited 206 56.34 27.3 (0.80, 1.08) 
55+ Uninvited 226 71.13 31.5 0.81 
Invited 744 188.62 25.4 (0.72, 0.91) 
50–64 Uninvited 451 137.01 30.4 0.85 
Invited 950 244.95 25.8 (0.78, 0.93) Screening-induced breast cancer mortality reduction in East Anglia 427
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already been made with the change towards using higher mammo-
graphic film density (Young et al, 1997). 
There are advantages in predicting – rather than directly
observing – changes in mortality. Firstly, results are available soon
after completion of the second screening round; several years
before sufficient mortality data have accrued. Secondly, the evalua-
tion considers essentially a single population of women, before and
after invitation to screening: cancers in the invited and uninvited
study groups are diagnosed over essentially the same time period,
and results are based on pathological measures of disease extent at
diagnosis. They are therefore unaffected by temporal changes in
treatment or in changing incidence or stage at presentation caused
either by variation in the underlying risk of disease or by participa-
tion bias due to socioeconomic or other differences. A final strength
of our approach is the increased power obtained by using predicted
mortality, hence the narrow confidence intervals for the relative
mortalities in Table 4. If the relative risk of 0.85 for the age group
50–64, with 36 months lead time, had been based on 137 and 245
observed deaths, the confidence interval would be 0.72, 1.01. Using
predicted deaths, the confidence interval is roughly half the width.
We can thus estimate more precisely the magnitude of the impact of
screening on mortality (Day and Duffy, 1996). 
The main drawback to using predicted mortality for assessing
screening programme performance is the reliance on the under-
lying model. However the approach we have used here has been
shown to predict mortality in the Swedish two-county study with
considerable accuracy (Tabar et al, 1995). Furthermore, although
the predicted effect on mortality is determined by the effects on
survival of tumour size, grade and node status estimated using East
Anglia data, we obtained very similar estimates of predicted
mortality reduction using a completely separate source (the
Swedish two-county study) for survival information based on
prognostic factors. This concordance supports the robustness of
the method. 
Recently population-based breast screening programmes have
come under attack with highly publicized reports of lack of effect-
iveness (Sjönell and Ståhle, 1999; Gøtzsche and Olsen, 2000). In
welcome contrast our results indicate that, despite rates for interval
cancers that were initially higher than expected (Day et al, 1995;
Woodman et al, 1995), the second round of screening in East
Anglia should deliver a substantial mortality reduction through its
effects on tumour size, grade and node status. Given similar distri-
butions of prognostic characteristics amongst cancers in screened
and non-screened women, we would expect other regional
programmes to achieve similar impact, although clearly there may
be some variation between regional programmes due to differ-
ences in screening performance and effectiveness of treatment.
However we estimate that, independently of any reduction
expected due to changes in treatment and underlying disease,
screening throughout the East Anglian region should reduce breast
cancer deaths by around a further 19% in women aged 55–64 at
diagnosis by the year 2004. 
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